Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-828

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-828). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 828 26 Master Bottle Label Approval Rev A 02 22)

Label for Losartan Potassium Tablets USP 100 mg, film-coated oral tablets, in a package containing 90 tablets. The label states prescription use only and storage instructions. It is labeled by Northwind Health Company, LLC with NDC 51655-828.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium and Atenolol. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021, illustrating patient outcome trends over time for each treatment group.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over a 66-month study period for Losartan Potassium and Atenolol. The graph illustrates a lower stroke incidence for Losartan Potassium compared to Atenolol, highlighting an adjusted risk reduction of 25% with significant statistical notation (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol event rates. The chart displays hazard ratios and 95% confidence intervals for primary composite outcomes and stroke (fatal and non-fatal) events, segmented by variables including age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. Symbols reflect sample sizes and hazard ratios indicate comparative favorability between the two drugs.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and Placebo groups, showing risk reduction percentage and p-value. The x-axis represents time in months, and the y-axis represents the percentage of patients with events.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium displayed as a molecular drawing with labeled atoms including chlorine, potassium ion, and various rings connected by bonds, representing the active ingredient in the drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.